The Germantown Innovation Center is home to some of Maryland’s fastest-rising stars in the life sciences ecosystem. Multiple startups found a home in the Montgomery County incubator and benefit from the lab space and the strategic access to federal agencies, nearby thought leadership, and on-campus workforce access.
Raj Vora is a Life Sciences Core Market Leader, Responsible for business growth, technical expertise, and account management of the DPR Construction’s life sciences portfolio in the region through project and customer development or project-specific roles. Focused on cGMP manufacturing facilities primarily in the cell and gene therapy market and involved in lab, containment, and other research projects.
The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.
Gyroscope Therapeutics, a British gene therapy company that has U.S. operations in King of Prussia, has raised $148 million in venture capital funding.
The five-year-old company has now raised about $265 million over three funding rounds since its inception.
Gyroscope’s Series C financing was led by Forbion’s Growth Opportunities Fund. Other investors are Sofinnova Investments, funds and accounts advised by T. Rowe Price Associates, Tetragon Financial Group Limited, an undisclosed healthcare focused fund, Fosun Pharma, Cambridge Innovation Capital and founding investor Syncona.
The five-year-old company plans to use the proceeds from the stock sale to advance the development of its lead gene therapy candidate, GT005, a potential treatment for geographic atrophy secondary to age-related macular degeneration.
As some are now calling it, the greater Philadelphia region, or ‘Cellecon Valley, is garnering a lot of attention these days as a rapidly emerging Biopharma cluster, earning a defining spot among the top 10 clusters in the US.
Danielle Kalkofen is a molecular cell biologist and biochemist with 15 years of industry and academic experience. In 2015, she turned her focus to biological assay development, leading cross-functional teams to develop, validate, and commercialize new pathogen detection assay products.
About a year ago, BioBuzz attended the grand opening of Vigene Biosciences (Vigene) brand new headquarters in Rockville, Maryland. It was a fantastic day for Vigene, the BioHealth Capital Region (BHCR), and for the patients and families of people suffering from cancer and rare genetic diseases.
At BioBuzz, we’ve written extensively about the promise of cell and gene therapeutics for both patients and the companies developing these revolutionary personalized medicines.
The following op-ed, originally posted on CellandGene.com, was written by CEO Council Executive Director Claire Greenwood and Patricia Day, Manager, Leadership Engagement, Chamber of Commerce for Greater Philadelphia. On the heels of a 2020 study predicting substantial job growth in the cell and gene therapy sector in Greater Philadelphia, industry leaders in our
$7.50 per share
